<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109281</article-id><article-id pub-id-type="publisher-id">ACM-37514</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_15976415.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  卡双平治疗新诊断2型糖尿病患者的疗效及安全性研究
  Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>雷</surname><given-names>莎</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>筠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>同济大学附属同济医院内分泌代谢科，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>1869</fpage><lpage>1873</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察卡双平(吡格列酮二甲双胍)治疗新诊断2型糖尿病(type 2 diabetes mellitus, T2DM)患者的疗效及安全性。方法：选取35例新诊断的T2DM患者，观察卡双平治疗12周后糖化血红蛋白(hemoglobin A1c，HbA1c)及空腹血糖(fasting plasma glucose, FPG)的变化，明确药物的疗效及不良反应。结果：经过卡双平12周治疗后，新诊断的T2DM患者HbA1c及FPG水平明显下降(P &lt; 0.05)，而且没有严重不良反应发生(P &gt; 0.05)。结论：卡双平治疗新诊断的T2DM患者疗效确切，不良反应发生率低，可作为新诊断T2DM患者的治疗方案之一。
    Objective: To examine the efficacy and safety of pioglitazone/metformin fixed-dose combination therapy in a twice-daily regimen over 12 weeks treatment in newly diagnosed T2DM patients. Methods: 35 cases newly diagnosed T2DM patients were recruited. The changes of HbA1c, FPG and adverse events were evaluated at 12 weeks. Results: After 12 weeks treatment, HbA1c and FPG were significantly decreased compared with baseline. The pioglitazone/metformin fixed-dose combination was well tolerated with no unexpected findings in adverse events. Conclusions: The pioglitazone/metformin fixed-dose combination exhibits an excellent efficacy and safety for T2DM, which is a selection for those patients with newly diagnosed T2DM. 
  
 
</p></abstract><kwd-group><kwd>2型糖尿病，吡格列酮二甲双胍，血糖，糖化血红蛋白, T2DM</kwd><kwd> Pioglitazone/Metformin Fixed-Dose Combination</kwd><kwd> Glycemic</kwd><kwd> HbA1c</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察卡双平(吡格列酮二甲双胍)治疗新诊断2型糖尿病(type 2 diabetes mellitus, T2DM)患者的疗效及安全性。方法：选取35例新诊断的T2DM患者，观察卡双平治疗12周后糖化血红蛋白(hemoglobin A1c，HbA1c)及空腹血糖(fasting plasma glucose, FPG)的变化，明确药物的疗效及不良反应。结果：经过卡双平12周治疗后，新诊断的T2DM患者HbA1c及FPG水平明显下降(P &lt; 0.05)，而且没有严重不良反应发生(P &gt; 0.05)。结论：卡双平治疗新诊断的T2DM患者疗效确切，不良反应发生率低，可作为新诊断T2DM患者的治疗方案之一。</p></sec><sec id="s2"><title>关键词</title><p>2型糖尿病，吡格列酮二甲双胍，血糖，糖化血红蛋白</p></sec><sec id="s3"><title>Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM<sup> </sup></title><p>Sha Lei, Yun Zhou<sup>*</sup></p><p>Department of Endocrinology, Tongji Hospital, Tongji University School of Medicine, Shanghai</p><p><img src="//html.hanspub.org/file/1-1571521x5_hanspub.png" /></p><p>Received: Aug. 17<sup>th</sup>, 2020; accepted: Sep. 1<sup>st</sup>, 2020; published: Sep. 8<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/1-1571521x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To examine the efficacy and safety of pioglitazone/metformin fixed-dose combination therapy in a twice-daily regimen over 12 weeks treatment in newly diagnosed T2DM patients. Methods: 35 cases newly diagnosed T2DM patients were recruited. The changes of HbA1c, FPG and adverse events were evaluated at 12 weeks. Results: After 12 weeks treatment, HbA1c and FPG were significantly decreased compared with baseline. The pioglitazone/metformin fixed-dose combination was well tolerated with no unexpected findings in adverse events. Conclusions: The pioglitazone/metformin fixed-dose combination exhibits an excellent efficacy and safety for T2DM, which is a selection for those patients with newly diagnosed T2DM.</p><p>Keywords:T2DM, Pioglitazone/Metformin Fixed-Dose Combination, Glycemic, HbA1c</p><disp-formula id="hanspub.37514-formula2"><graphic xlink:href="//html.hanspub.org/file/1-1571521x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1571521x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1571521x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>全球T2DM的发病率急剧增加，大型临床研究显示良好的血糖控制可以延缓疾病进展，减少微血管并发症的发生 [<xref ref-type="bibr" rid="hanspub.37514-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.37514-ref2">2</xref>]。英国的糖尿病前瞻性研究(UKPDS)结果所示，HbA1c每下降1%，微血管并发症的发生风险下降37% [<xref ref-type="bibr" rid="hanspub.37514-ref3">3</xref>]。而且在疾病早期的血糖控制对于减少大血管并发症也十分重要。UKPDS的10年随访研究发现早期的强化控制血糖可以减少心梗、全因死亡等大血管并发症的发生风险 [<xref ref-type="bibr" rid="hanspub.37514-ref4">4</xref>]。</p><p>目前不同作用机制的口服降糖药物联合治疗在T2DM的临床应用中已经十分广泛。T2DM患者早期联合药物治疗能更早达到控糖目标，延缓糖尿病的发展进程。吡格列酮二甲双胍片(卡双平)复方制剂两药作用机制互补，能改善T2DM患者的胰岛素抵抗，有效控制血糖，减少心血管并发症 [<xref ref-type="bibr" rid="hanspub.37514-ref5">5</xref>]，同时提高患者的用药依从性，达到长期控糖效果，是国内外指南推荐的首选治疗方案之一 [<xref ref-type="bibr" rid="hanspub.37514-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.37514-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37514-ref8">8</xref>]。本研究通过观察新诊断的T2DM患者应用吡格列酮二甲双胍治疗后的血糖变化并进行安全性评价。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>该研究选取2019年1月至2019年12月在同济大学附属同济医院内分泌科门诊就诊的初发T2DM患者35例，根据中国T2DM防治指南 [<xref ref-type="bibr" rid="hanspub.37514-ref7">7</xref>] 的诊断标准确诊。入选标准：1) 新诊断的T2DM患者，HbA1c水平7.5%~11.0%；2) 年龄18~70岁；3) 至少包含以下其中一项：脂肪肝；男性腰围 &gt; 90 cm，女性 &gt; 85 cm；BMI 21~35 Kg/m<sup>2</sup>。研究方案符合同济大学附属同济医院临床伦理委员会所制定的伦理学标准并得到伦理委员会的批准。</p><p>排除标准：1) 已经诊断T2DM的患者；2) 1型糖尿病或其他类型的糖尿病；3) 肾功能不全，eGFR &lt; 45 ml/min；4) 肝功能不全，谷丙转氨酶和(或)谷草转氨酶大于正常高值3倍以上；5) 严重心脑血管疾病者；6) 糖尿病急性并发症；7) 心功能不全者；8) 慢性胃肠道疾病者；9) 其他研究者认为不适于参加本研究的患者。所有参与本研究的患者均自愿参与，并知情。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>所有入选的患者均进行糖尿病饮食及运动控制、糖尿病健康宣教等基础措施。入组后所有患者予卡双平(吡格列酮二甲双胍，杭州中美华东制药有限公司)治疗，每日2次，每次1片口服治疗，随访周期为12周，观察12周后患者的FPG、HbA1c的变化及有无不良反应。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>1) 所有研究对象于治疗前后在空腹状态下进行FPG、HbA1c的检测；2) 在治疗过程中记录严重低血糖、水肿及心血管事件(急性心肌梗死、心力衰竭)的发生情况。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>应用GraphPad Prism 6.0软件进行统计分析，所有正态分布的计量资料以 x &#175; &#177; S E M (均值 &#177; 标准误)表示，采用配对样本t检验来比较治疗前后的疗效。P &lt; 0.05认为具有统计学差异，P &lt; 0.05用*表示，P &lt; 0.01用**表示，P &lt; 0.001用***表示。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 卡双平治疗后的疗效分析</title><p>本研究共纳入35例研究对象，其中男性21例，女性14例，平均年龄(55.54 &#177; 12.33)岁。如图1所示，基线的初发T2DM患者的平均HbA1c是9.65%，经过卡双平的12周治疗后，HbA1c下降2.78%，</p><p>图1. 卡双平治疗前后HbA1c的变化</p><p>图2. 卡双平治疗前后FPG的变化</p><p>二者之间的差异具有统计学意义(P &lt; 0.001)。如图2所示，与基线相比，治疗12周后，FPG也明显下降(9.45 mmol/L vs 7.92 mmol/L)，二者差异有统计学意义(P &lt; 0.001)。</p></sec><sec id="s7_2"><title>3.2. 卡双平的安全性评价</title><p>经过卡双平的12周治疗后，所有患者都没有出现不良反应，不良反应发生率为0% (P &gt; 0.05)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>T2DM以胰岛素抵抗和β细胞功能受损为特征。胰岛素抵抗不仅可以影响血糖，而且经常伴随着高血压、脂代谢异常和心血管疾病，存在于整个糖尿病的病程。噻唑烷二酮类(TZDs)药物作为胰岛素增敏剂，通过激活过氧化物酶体增殖激活物受体γ (peroxisome proliferators-activated receptor γ, PPAR-γ)增加外周组织对胰岛素的敏感性，从而改善胰岛素抵抗、降低血糖和高胰岛素血症。二甲双胍通过抑制肝糖原输出，改善胰岛素抵抗，是目前各大指南推荐的T2DM的一线用药。</p><p>吡格列酮二甲双胍作为一种复方制剂，二者联合可以降低HbA1c和FPG水平，维持长时间较好的血糖控制。本研究选取新诊断的T2DM患者，观察吡格列酮二甲双胍的疗效及安全性，发现经过12周的治疗后HbA1c平均下降2.78%，FPG也得到有效控制，而且没有出现明显的不良反应。</p><p>我们的研究结果与大量临床研究的结果相一致。Derosa等对271例超重且血糖控制不佳的T2DM患者，随机分为吡格列酮组、二甲双胍组、吡格列酮联合二甲双胍组，分别在3个月和15个月后进行血糖正常的高胰岛素钳夹技术，发现吡格列酮二甲双胍组的患者HbA1c、FPG和餐后血糖明显下降，而且可以显著改善胰岛素抵抗的相关参数 [<xref ref-type="bibr" rid="hanspub.37514-ref9">9</xref>]。另外，有多项研究显示，不论是吡格列酮二甲双胍复方制剂还是在二甲双胍单药血糖控制不佳基础上加用吡格列酮，均可以显著改善HbA1c及FPG水平，而且与单药组相比，没有出现新的不良反应 [<xref ref-type="bibr" rid="hanspub.37514-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37514-ref11">11</xref>]。</p><p>吡格列酮二甲双胍复方制剂不仅有良好的降糖疗效，而且可以改善血脂水平，调节心血管风险的炎症标志物水平，减少心血管疾病的发生风险。Perez等人研究发现吡格列酮二甲双胍复方制剂可以增加HDL-C，减少TG，明显降低小的低密度脂蛋白和增加大的低密度脂蛋白颗粒浓度，同时能够降低C反应蛋白(C-reactive protein, CRP)的水平和升高脂联素水平，改善心血管疾病相关的危险因素 [<xref ref-type="bibr" rid="hanspub.37514-ref12">12</xref>]。另外，有研究显示噻唑烷二酮类药物还可以调节炎症因子的表达，包括CRP、基质金属蛋白酶9 (matrix metalloprotein, MMP 9)、白介素6 (interleukin-6, IL-6)和肿瘤坏死因子α (tumor necrosis factor α, TNF-α)及单核细胞化学趋化蛋白-1 (monocyte chemotactic protein-1, MCP-1)，降低颈动脉内膜厚度 [<xref ref-type="bibr" rid="hanspub.37514-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.37514-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.37514-ref15">15</xref>]，从而减少大血管并发症的发生风险。</p><p>因此，吡格列酮二甲双胍复方制剂通过不同机制明显改善初发T2DM的血糖和HbA1c水平，疗效确切，不良反应发生率低。而且该药服用简便、患者依从性高，胃肠道反应少，能一定程度减轻患者的经济负担，延缓T2DM患者并发症的进展，可作为新诊断T2DM患者的治疗方案之一。</p></sec><sec id="s9"><title>文章引用</title><p>雷 莎,周 筠. 卡双平治疗新诊断2型糖尿病患者的疗效及安全性研究Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM[J]. 临床医学进展, 2020, 10(09): 1869-1873. https://doi.org/10.12677/ACM.2020.109281</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37514-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">UK Prospective Diabetes Study Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). The Lancet, 352, 837-853. &lt;br&gt;https://doi.org/10.1016/S0140-6736(98)07019-6</mixed-citation></ref><ref id="hanspub.37514-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">UK Prospective Diabetes Study Group (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet, 352, 854-865.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(98)07037-8</mixed-citation></ref><ref id="hanspub.37514-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Stratton, M.I. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412. &lt;br&gt;https://doi.org/10.1136/bmj.321.7258.405</mixed-citation></ref><ref id="hanspub.37514-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Holman, R.R., Paul, S.K., Angelyn Bethel, M., et al. (2008) 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 359, 1577-1589. &lt;br&gt;https://doi.org/10.1056/NEJMoa0806470</mixed-citation></ref><ref id="hanspub.37514-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J.W., Kang, S.C., Joh, H.-K., Kwon, H., Kim, J. and Park, D. (2017) Comparative Effectiveness of Oral Antidiabetic Drugs in Preventing Cardiovascular Mortality and Morbidity: A Network Meta-Analysis. PLoS ONE, 12, e0177646. &lt;br&gt;https://doi.org/10.1371/journal.pone.0177646</mixed-citation></ref><ref id="hanspub.37514-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">朱大龙, 母义明, 翁建平, 等. 吡格列酮二甲双胍复方制剂临床应用专家建议[J]. 中国糖尿病杂志, 2017, 25(12): 1057-1063.</mixed-citation></ref><ref id="hanspub.37514-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344.</mixed-citation></ref><ref id="hanspub.37514-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., et al. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 23, 1-87. &lt;br&gt;https://doi.org/10.4158/EP171764.APPGL</mixed-citation></ref><ref id="hanspub.37514-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Derosa, G., Maffioli, P., Salvadeo, S.A.T., et al. (2009) Direct Comparison among Oral Hypoglycemic Agents and Their Association with Insulin Resistance Evaluated by Euglycemic Hyperinsulinemic Clamp: The 60’s Study. Metabolism, 58, 1059-1066. &lt;br&gt;https://doi.org/10.1016/j.metabol.2009.03.007</mixed-citation></ref><ref id="hanspub.37514-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Perez, A., Zhao, Z., Jacks, R. and Spanheimer, R. (2009) Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy Compared with Pioglitazone and Metformin Monotherapy in Treating Patients with T2DM. Current Medical Research &amp; Opinion, 25, 2915-2923. &lt;br&gt;https://doi.org/10.1185/03007990903350011</mixed-citation></ref><ref id="hanspub.37514-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Einhorn, D., Rendell, M., Rosenzweig, J., et al. (2000) Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study. Clinical Therapeutics, 22, 1395-1409.  
&lt;br&gt;https://doi.org/10.1016/S0149-2918(00)83039-8</mixed-citation></ref><ref id="hanspub.37514-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Perez, A., Jacks, R., Arora, V. and Spanheimer, R. (2010) Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared with Pioglitazone and Metformin Monotherapy in Patients with Type 2 Diabetes. Journal of Clinical Hypertension, 12, 973-982.  
&lt;br&gt;https://doi.org/10.1111/j.1751-7176.2010.00389.x</mixed-citation></ref><ref id="hanspub.37514-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Andreas, P., Nikolaus, M., Georg, L., Langenfeld, M., Walcher, D., Konrad, T. and Forst, T. (2005) Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent from Glycemic Control: Results from the Pioneer Study. Journal of the American College of Cardiology, 45, 1925-1931. &lt;br&gt;https://doi.org/10.1016/j.jacc.2005.03.041</mixed-citation></ref><ref id="hanspub.37514-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mazzone, T., Meyer, P.M., Feinstein, S.B., et al. (2006) Effect of Pioglitazone Compared with Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial. JAMA, 296, 2572-2581.  
&lt;br&gt;https://doi.org/10.1001/jama.296.21.joc60158</mixed-citation></ref><ref id="hanspub.37514-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chu, N.V., Kong, A.P.S., Kim, D.D., et al. (2002) Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients with Type 2 Diabetes. Diabetes Care, 25, 542-549. &lt;br&gt;https://doi.org/10.2337/diacare.25.3.542</mixed-citation></ref></ref-list></back></article>